Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard Ultra Short Bond ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Vanguard Ultra Short Bond ETF trades at $49.48 (market cap $10.20B). The key difference: Vanguard Ultra Short Bond ETF is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard Ultra Short Bond ETF for 64 Days on average.
| SYRE | VUSB | |
|---|---|---|
Market Cap | $7.52B | $10.20B |
Volume | 1,441,031 | 1,227,697 |
Sector | Health | Leveraged / Inverse |
52-Week High | $108.92 | $50.03 |
52-Week Low | $22.18 | $49.41 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VUSB is trading at $49.475, showing minimal daily movement with a slight decline of 0.01%. Technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The ETF maintains consistent dividend distributions, with recent payments of $0.17-0.18 per share. Market sentiment is influenced by Federal Reserve interest rate expectations, positioning short-term bond ETFs favorably amid potential rate increases.
The outlook for VUSB remains cautious due to bearish technical signals and interest rate sensitivity. Investment opportunity exists for investors seeking short-term bond exposure with regular income, though risks include Fed policy shifts and market volatility. The ETF's stability and dividend consistency provide defensive characteristics in uncertain rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
